GSK Clarifies Stance on Leucovorin Label Update for Autism Treatment

FDA Action on Leucovorin

• 🎯 The FDA is moving forward with approving Leucovorin for the treatment of some symptoms associated with autism.
• 💡 This action is primarily to update the drug's label, which is crucial for generic drug manufacturers.

GSK's Position and Market Strategy

• 🚫 A GSK spokesperson stated that the company has no intention to market Leucovorin, even if the FDA approves the label update.
• 📉 GSK previously withdrew its brand-name version of the drug from the market in 1997.
• 📈 Despite this clarification, GSK's stock saw a 2% increase.
• 📌 GSK's primary interest in the label update is to ensure it trickles down to generics that are currently available.